



## **Design Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference**

May 28, 2026

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat during the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 1:25 p.m. ET in New York.

A live webcast of the fireside chat will be available [here](#) and in the investors section of the company's website at [www.designtx.com](http://www.designtx.com). The webcast will be archived for at least 30 days following each presentation.

### **About Design Therapeutics**

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC<sup>®</sup> gene targeted chimera small molecules. The company's GeneTAC<sup>®</sup> molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC<sup>®</sup> programs, DT-216P2, in development for patients with Friedreich ataxia, DT-168, for Fuchs endothelial corneal dystrophy, and DT-818, for myotonic dystrophy type-1, the company is advancing a program in Huntington's disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit [designtx.com](http://designtx.com).

### **Contact:**

Renee Leck, THRUST  
[renee@thrustsc.com](mailto:renee@thrustsc.com)